Treatment schedules for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration

This is the protocol for a review and there is no abstract. The objectives are as follows: To investigate the effects of non-monthly versus monthly intravitreal injection of an anti-VEGF agent on best-corrected visual acuity (BCVA) in people with newly diagnosed nAMD at one-year follow-up.